Porter, J.M.; Guerassimoff, L.; Castiello, F.R.; Charette, A.; Tabrizian, M.
INGAP-Peptide Variants as a Novel Therapy for Type 1 Diabetes: Effect on Human Islet Insulin Secretion and Gene Expression. Pharmaceutics 2022, 14, 1833.
https://doi.org/10.3390/pharmaceutics14091833
AMA Style
Porter JM, Guerassimoff L, Castiello FR, Charette A, Tabrizian M.
INGAP-Peptide Variants as a Novel Therapy for Type 1 Diabetes: Effect on Human Islet Insulin Secretion and Gene Expression. Pharmaceutics. 2022; 14(9):1833.
https://doi.org/10.3390/pharmaceutics14091833
Chicago/Turabian Style
Porter, James M., Léa Guerassimoff, Francisco Rafael Castiello, André Charette, and Maryam Tabrizian.
2022. "INGAP-Peptide Variants as a Novel Therapy for Type 1 Diabetes: Effect on Human Islet Insulin Secretion and Gene Expression" Pharmaceutics 14, no. 9: 1833.
https://doi.org/10.3390/pharmaceutics14091833
APA Style
Porter, J. M., Guerassimoff, L., Castiello, F. R., Charette, A., & Tabrizian, M.
(2022). INGAP-Peptide Variants as a Novel Therapy for Type 1 Diabetes: Effect on Human Islet Insulin Secretion and Gene Expression. Pharmaceutics, 14(9), 1833.
https://doi.org/10.3390/pharmaceutics14091833